Conditions

This post was originally published on this site A combination of Lynparza (olaparib) and the investigational PI3K inhibitor alpelisib is safe for the treatment of recurrent epithelial ovarian cancer and induces at least stable disease in more than 80% of patients, results from a Phase 1 trial show. Importantly, the combination was effective in women…

This post was originally published on this site 68Ga-PSMA-11 PET scans are highly accurate, reproducible, and safe for detecting prostate cancer that has come back after prior therapy with prostate surgery or radiation therapy, a study shows. The report, “Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer,” was published in the journal JAMA Oncology.…

This post was originally published on this site Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about three times more likely to respond to treatment with checkpoint blockade immunotherapies, according to a study. The findings…

This post was originally published on this site Chronic B-cell activation — which can happen because of infectious mononucleosis, commonly caused by the Epstein-Barr virus (EBV) — triggers an excessive proliferation of certain B cells, which can evolve into a B-cell lymphoma. Although such chronic activation alone is not sufficient to drive cancer onset, vaccinating against EBV may work to…

This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the multiple myeloma field and to advance new treatments. The $50 million independent, self-sustaining fund is focused on accelerating the foundation’s mission to deliver precision…

This post was originally published on this site Lumicell is assessing its LUM Imaging System as a means to help surgeons better detect cancer cells that spread into the peritoneum — the membrane lining the abdominal cavity and covering the abdominal organs – during surgery, the company announced. The clinical trial (NCT03834272) — which is…

This post was originally published on this site Treatment with a liposomal formulation of irinotecan — meaning the chemotherapy is wrapped up in tiny fatty spheres —was well-tolerated and partially reduced the tumor burden in 35% of heavily pretreated breast cancer patients in a Phase 1 clinical trial, including those with brain metastasis. Results were…

This post was originally published on this site Aprea Therapeutics‘ APR-246 stabilizes the tumor suppressor protein p53, boosting responses to checkpoint blockade immunotherapies in mouse models of melanoma and colorectal cancer, a study says. Findings were announced in a press release and featured on the poster, “TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade…

This post was originally published on this site A combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) is better at delaying disease progression and extending survival of patients with locally advanced prostate cancer than ADT alone, a Phase 3 trial shows. The study, “Long‐term androgen deprivation, with or without radiotherapy, in…